Gilead, Morgan Stanley

Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its next-gen HIV treatment strategy.
Morgan Stanley Upgrades Gilead Sciences (GILD)
Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 13.08% Upside As of December 23,
Gilead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug developer shared initial mid-stage trial data for two antitumor agents developed using Sanofi’s (SNY) PRO-XTEN masking platform.
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The analysts flagged
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
This was the stock's fifth consecutive day of losses.
ENDPOINTS NEWS21h
Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...
FierceBiotech2d
Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
BioPharma Dive1d
Galapagos, after research struggles, will split in two and revamp Gilead deal
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
This was the stock's fourth consecutive day of losses.
bovnews2d
BofA Securities Just Resumed Gilead Sciences Inc (GILD) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...
Gilead price target lowered to $83 from $84 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...